5-nonanone thiosemicarbazone | 22397-20-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-nonanone thiosemicarbazone
• 英文别名: 5-Nonanone, thiosemicarbazone；(nonan-5-ylideneamino)thiourea
• CAS: 22397-20-2
• 化学式: C₁₀H₂₁N₃S
• 分子量: 215.363
• InChiKey: YPXYZYZVDSWSKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  51.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  catechol isopropylborate 、 5-nonanone thiosemicarbazone 以 苯 为溶剂， 以79%的产率得到
  参考文献：
  名称：

  Bhal, L.; Singh, R. V.; Tandon, J. P., Acta Chimica Hungarica, 1984, vol. 115, # 3, p. 251 - 260

  摘要：

  DOI：

文献信息

• Thiadiazoline derivative
  申请人：Murakata Chikara

  公开号：US20060074113A1

  公开（公告）日：2006-04-06

  (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

  提供了一种抗肿瘤剂，其中R1和R4相同或不同，每个代表氢原子，取代或未取代的低级烷基，取代或未取代的低级炔基，取代或未取代的低级烯基或类似物；R5代表取代或未取代的杂环基，取代或未取代的芳基或类似物；R2代表-C（═W）R6或类似物；R3代表氢原子，-C（═WA）R6A或类似物。该抗肿瘤剂包含由上述通式（I）表示的噻二唑啉衍生物或其药理学上可接受的盐作为活性成分。
• THIADIAZOLINE DERIVATIVE
  申请人：MURAKATA Chikara

  公开号：US20080207706A1

  公开（公告）日：2008-08-28

  (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

  提供了一种抗肿瘤剂，其包括由上述一般式（I）表示的噻二唑啉衍生物或其药学上可接受的盐作为活性成分，其中R1和R4相同或不同，每个代表氢原子，取代或未取代的低碳基，取代或未取代的低炔基，取代或未取代的低烯基或类似物; R5代表取代或未取代的杂环基，取代或未取代的芳基或类似物; R2代表-C（═W）R6或类似物; R3代表氢原子，-C（═WA）R6A或类似物。
• Mitotic kinesin inhibitor
  申请人：Murakata Chikara

  公开号：US20070155804A1

  公开（公告）日：2007-07-05

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂动力蛋白Eg5抑制剂，其包括由通式（I）表示的噻二唑衍生物或其药学上可接受的盐作为活性成分：[其中R1代表氢原子等，R2代表氢原子，-C（═W）R6（其中W代表氧原子或硫原子，R6代表取代或未取代的低级烷基等）等，R3代表-C（═Z）R19（其中Z代表氧原子或硫原子，R19代表取代或未取代的低级烷基等）等，R4代表取代或未取代的低级烷基等，R5代表取代或未取代的芳基等]等。
• Mitotic Kinesin Inhibitor
  申请人：KATO Kazuhiko

  公开号：US20110275827A1

  公开（公告）日：2011-11-10

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂动力蛋白Eg5抑制剂，该抑制剂包括由通式（I）所表示的噻二唑衍生物或其药学上可接受的盐作为活性成分：[其中R1表示氢原子等，R2表示氢原子，-C（═W）R6（其中W表示氧原子或硫原子，R6表示取代或未取代的低碳基等）等，R3表示-C（═Z）R19（其中Z表示氧原子或硫原子，R19表示取代或未取代的低碳基等）等，R4表示取代或未取代的低碳基等，R5表示取代或未取代的芳基等]等。
• M-STAGE KINESIN INHIBITOR
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1616866A1

  公开（公告）日：2006-01-18

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, -C(=W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents -C(=Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂驱动蛋白 Eg5 抑制剂，其活性成分包括通式 (I) 所代表的噻二唑 啉衍生物或其药理学上可接受的盐： [其中 R1 代表氢原子等，R2 代表氢原子、-C(＝W)R6（其中 W 代表氧原子或硫原子，R6 代表取代或未取代的低级烷基等）等，R3 代表-C(＝Z)R19（其中 Z 代表氧原子或硫原子、R4代表取代或未取代的低级烷基等，R5代表取代或未取代的芳基等]等。